Drugs & Targets FDA approves Zynyz as first-line treatment for advanced anal cancer May 16, 2025Vol.51 No.19
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent LGSOC May 09, 2025Vol.51 No.18
Drugs & Targets EU approves Calquence + chemo as first and only BTK inhibitor for first-line MLC May 09, 2025Vol.51 No.18
Drugs & Targets CHMP adopts positive opinion for Adcetris + ECADD for newly diagnosed stage IIb/III/IV Hodgkin lymphoma May 02, 2025Vol.51 No.17
Drugs & Targets CHMP adopts positive opinion on Calquence-based regimens for CLL May 02, 2025Vol.51 No.17
Drugs & Targets FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma April 25, 2025Vol.51 No.16
Drugs & Targets FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma April 25, 2025Vol.51 No.16
Drugs & Targets FDA approves nivolumab + ipilimumab for unresectable or metastatic HCC April 18, 2025Vol.51 No.15
Drugs & Targets FDA to phase out animal testing requirement for monoclonal antibodies, other drugs April 18, 2025Vol.51 No.15
